New research about PAH

October 24, 2007



(Tuesday, October 23, 1:30 PM EST)

A new US-based study entitled, The Registry to Evaluate Early And Long-term PAH Disease Management (REVEAL), has been implemented at 50 sites in the US, for the purpose of gathering current and reliable information about the demographics, clinical course, and management of patients with pulmonary arterial hypertension (PAH). Patients will be followed for 5 years, and there are currently 1,226 patients enrolled in the registry. Researchers and representatives from Duke University, the Universities of Colorado, Alabama, and Oklahoma, and Actelion Pharmaceuticals suggest the registry will provide a large data set on PAH, which will allow the investigative community to address clinically important questions.



(Wednesday, October 24, 1:30 PM EST)

As part of an observational, US-based study, the REVEAL Registry has identified a significant delay in the period spanning symptom onset and the time to diagnosis of pulmonary arterial hypertension (PAH). Researchers and representatives from LDS Hospital, Boston University, Baylor College, the University of Utah, and the Ovation Research Group examined the records of REVEAL enrollees who had physician diagnosed PAH. They found that most of the patients experienced a significant delay between first symptoms and time to diagnosis, with most experiencing a year-long delay. They also note that 25 percent experienced a delay of up to 3-years.



(Wednesday, October 24, 3:00 PM EST)

Sildenafil may be the best treatment for pulmonary arterial hypertension (PAH), according to new research. The study, from the Medical University of South Carolina, found that when compared to six other treatments, Sildenafil was the most inexpensive, and resulted in a greater gain in quality-adjusted life years. Researchers suggest physicians take the life-styles of their patients into account when prescribing PAH medications.

American College of Chest Physicians

Related Pulmonary Arterial Hypertension Articles from Brightsurf:

Adding another dimension to a cell culture model for pulmonary arterial hypertension
Pulmonary arterial hypertension is a rare disease in which excessive proliferation of the cells of pulmonary arterial walls obstructs the blood flow in the lungs.

Casting a wider net to catch more cases of pulmonary hypertension
Investigators took an evidence-based approach to determine the lower end of the risk spectrum for PH based on pulmonary vascular resistance (PVR), which is resistance against blood flow from the pulmonary artery to the lungs.

Fusion protein holds promise for treating pulmonary arterial hypertension
In a paper published in Science Translational Medicine, researchers illuminate the underlying biological pathways that may lead to vessel destruction in pulmonary arterial hypertension.

New technical approach can enhance diagnosis of pulmonary hypertension
The management and prognosis of pulmonary hypertension heavily relies on whether the pathology is localized in pulmonary arteries or veins.

Specific gut bacteria may be associated with pulmonary arterial hypertension
Researchers have found a specific bacterial profile in the gut of people with pulmonary arterial hypertension, a chronic and progressive disease that causes constriction of arteries in the lungs.

Advancing an oral drug for pulmonary arterial hypertension
With a protein drug grown in the leaves of lettuce plants, the University of Pennsylvania's Henry Daniell and colleagues hope to provide new treatment options for patients with pulmonary arterial hypertension, a rare but deadly disease.

Antiarrhythmic drug identified as potential treatment for pulmonary arterial hypertension
High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a potentially fatal disease caused by obstruction of blood flow in the lungs.

Pulmonary arterial hypertension targeted for new treatment by Sheffield scientists
Scientists at the University of Sheffield, working in collaboration with drug and vaccine developer Kymab Ltd, Cambridge, have identified a novel antibody that has the potential to become a new treatment for pulmonary arterial hypertension (PAH).

Protein central to immune system function new target for treating pulmonary hypertension
A protein with a role in sensing cell damage and viral infections is a new target for the treatment of pulmonary hypertension, or increased blood pressure in the lungs, according to research led by Virginia Commonwealth University and the University of Sheffield in the United Kingdom.

Drug identified that could reverse pulmonary arterial hypertension
Scientists identify a safe drug that for the first time could treat -- and possibly reverse -- the thickening of lung artery walls in pulmonary arterial hypertension; clinical trial is expected in 2019.

Read More: Pulmonary Arterial Hypertension News and Pulmonary Arterial Hypertension Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to